Снижение сердечно-сосудистого риска: акцент на розувастатин

1. Agneta Å et al. Low-Risk Diet and Lifestyle Habits in the Primary Prevention of Myocardial Infarction in Men. J Am Coll Cardiol 2014; 64 (13): 1299–306.
2. Chiuve SE et al. Primary prevention of stroke by healthy lifestyle. Circulation 2008; 118 (9): 947–54.
3. Boekholdt SM, Hovingh GK, Mora S et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events. J Am Coll Cardiol 2014; 64 (5): 485–94.
4. Jones PH et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther 2004; 26 (9): 1388–99.
5. Ridker P, Danielson E, Fonseca FAH et al for the JUPITER study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–207.
6. Грацианский Н.А. Сверхнизкий уровень холестерина липопротеинов низкой плотности в первичной профилактике у людей с повышенным С-реактивным белком. Результаты испытания JUPITER. Кардиология. 2009; 1: 73–5. / Gratsianskii N.A. Sverkhnizkii uroven' kholesterina lipoproteinov nizkoi plotnosti v pervichnoi profilaktike u liudei s povyshennym S-reaktivnym belkom. Rezul'taty ispytaniia JUPITER. Kardiologiia. 2009; 1: 73–5. [in Russian]
7. Crouse JR 3rd, Raichlen JS, Riley WA et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima–media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297 (12): 1344–53.
8. Nissen SE, Nicolls SJ, Sapahi I et al. ASTEROID Investigators. Effect of very high intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 296 (13): 1556–65.
9. Rollefstad S, Ikdahl E, Hisdal J et al. Rosuvastatin induced carotid plaque regression in patients with inflammatory joint diseases: the RORA-AS study. Arthritis Rheumatol 2015; 67: 1718–28.
10. Ikdahl E, Hisdal J, Rollefstad S et al. Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study. Arthritis Res Ther 2015; 17: 279.
11. Kjekshus J, Apetre E, Barrias W et al for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 1–14.
12. Karlson BW et al. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. Am J Cardiol 2016; 117 (9): 1444–8.
13. Тарловская Е.И., Нечаева Г.И., Мальчикова С.В., Семенкин А.А. Прогнозирование влияния оригинального и генерического розувастатина на прямые медицинские затраты при вторичной профилактике у пациентов с хроническими формами ишемической болезни сердца. Кардиоваск. терапия и профилактика. 2015; 14 (4): 29–37. / Tarlovskaia E.I., Nechaeva G.I., Mal'chikova S.V., Semenkin A.A. Prognozirovanie vliianiia original'nogo i genericheskogo rozuvastatina na priamye meditsinskie zatraty pri vtorichnoi profilaktike u patsientov s khronicheskimi formami ishemicheskoi bolezni serdtsa. Kardiovask. terapiia i profilaktika. 2015; 14 (4): 29–37. [in Russian]

________________________________________________

1. Agneta Å et al. Low-Risk Diet and Lifestyle Habits in the Primary Prevention of Myocardial Infarction in Men. J Am Coll Cardiol 2014; 64 (13): 1299–306.
2. Chiuve SE et al. Primary prevention of stroke by healthy lifestyle. Circulation 2008; 118 (9): 947–54.
3. Boekholdt SM, Hovingh GK, Mora S et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events. J Am Coll Cardiol 2014; 64 (5): 485–94.
4. Jones PH et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther 2004; 26 (9): 1388–99.
5. Ridker P, Danielson E, Fonseca FAH et al for the JUPITER study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–207.
6. Gratsianskii N.A. Sverkhnizkii uroven' kholesterina lipoproteinov nizkoi plotnosti v pervichnoi profilaktike u liudei s povyshennym S-reaktivnym belkom. Rezul'taty ispytaniia JUPITER. Kardiologiia. 2009; 1: 73–5. [in Russian]
7. Crouse JR 3rd, Raichlen JS, Riley WA et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima–media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297 (12): 1344–53.
8. Nissen SE, Nicolls SJ, Sapahi I et al. ASTEROID Investigators. Effect of very high intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 296 (13): 1556–65.
9. Rollefstad S, Ikdahl E, Hisdal J et al. Rosuvastatin induced carotid plaque regression in patients with inflammatory joint diseases: the RORA-AS study. Arthritis Rheumatol 2015; 67: 1718–28.
10. Ikdahl E, Hisdal J, Rollefstad S et al. Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study. Arthritis Res Ther 2015; 17: 279.
11. Kjekshus J, Apetre E, Barrias W et al for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 1–14.
12. Karlson BW et al. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. Am J Cardiol 2016; 117 (9): 1444–8.
13. Tarlovskaia E.I., Nechaeva G.I., Mal'chikova S.V., Semenkin A.A. Prognozirovanie vliianiia original'nogo i genericheskogo rozuvastatina na priamye meditsinskie zatraty pri vtorichnoi profilaktike u patsientov s khronicheskimi formami ishemicheskoi bolezni serdtsa. Kardiovask. terapiia i profilaktika. 2015; 14 (4): 29–37. [in Russian]

Г.С.Аникин*1,2, И.К.Сторожук2, Я.Ю.Филязова2

1 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119992, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2 ФГБУ «Поликлиника №3 Управления делами Президента РФ». 129090, Россия, Москва, Грохольский пер., д. 31
*medi321@mail.ru

________________________________________________

G.S.Anikin*1,2, I.K.Storozhuk2, Ya.Yu.Filyazova2

1 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119992, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
2 Out-Patient Сlinic №3 of Administration of the President of Russian Federation. 129090, Russian Federation, Moscow, Grokhol'skii per., d. 31
*medi321@mail.ru